Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05396014 · ClinicalTrials.gov registry record · Phase 4
The BEST Trial: Biomarkers for Evaluating Spine Treatments
A Phase 4 study, sponsored by University of North Carolina, Chapel Hill.
- Completed
- Registry status
- Phase 4
- Development phase
- 1,014
- Enrollment target
NCT05396014 is a Phase 4 study that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 1,014 participants.
The verdict
NCT05396014, a Phase 4 study, has completed, sponsored by University of North Carolina, Chapel Hill.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 1,014 participants
- Enrollment target
Study Summary
The BEST Trial (Biomarkers for Evaluating Spine Treatments) is a National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)-sponsored clinical trial being conducted through the NIH Helping to End Addiction Long-term (HEAL) Initiative's Back Pain Consortium (BACPAC) Research Program. The primary objective of this trial is to inform a precision medicine approach to the treatment of Chronic Low-Back Pain by estimating the optimal treatment or combination of treatments based on patient features and response to the initial treatment. Interventions being evaluated in this trial are: (1) enhanced self-care (ESC), (2) acceptance and commitment therapy (ACT), (3) evidence-based exercise and manual therapy (EBEM), and (4) duloxetine.
Interventions
- DRUG Duloxetine
- BEHAVIORAL Acceptance and Commitment Therapy (ACT)
- BEHAVIORAL Enhanced Self-Care (ESC)
- BEHAVIORAL Evidence-Based Exercise and Manual Therapy (EBEM)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,014 participants |
| Start Date | 2022-09-12 |
| Est. Completion | 2024-10-22 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05396014
The ClinicalTrials.gov registry entry for NCT05396014 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 1,014 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of North Carolina, Chapel Hill, which has 1,109 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Duloxetine is the first listed.
NCT05396014 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05396014 about?
NCT05396014 is a clinical study titled "The BEST Trial: Biomarkers for Evaluating Spine Treatments". The BEST Trial (Biomarkers for Evaluating Spine Treatments) is a National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)-sponsored clinical trial being conducted through the NIH Helping to End Addiction Long-term (HEAL) Initiative's Back Pain Consortium (BACPAC) Research Progra...
What is the current status of trial NCT05396014?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 1,014 participants. The study started on 2022-09-12. Estimated completion is 2024-10-22.
What interventions are being tested in trial NCT05396014?
The interventions under investigation include: Duloxetine (DRUG), Acceptance and Commitment Therapy (ACT) (BEHAVIORAL), Enhanced Self-Care (ESC) (BEHAVIORAL), Evidence-Based Exercise and Manual Therapy (EBEM) (BEHAVIORAL).
Who is sponsoring clinical trial NCT05396014?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.